Presentations of the ESMO Magnitude of Clinical Benefit Scale

Since its publication in Annals for Oncology, the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) has been presented on a number of occasions 

ESMO 2017 Congress: September 2017

The scale will be presented or referenced during the following sessions at the ESMO 2017 congress:

Saturday, 9 September: Poster Discussion Session; 16:30-17:45,  Tarragona Auditorium

1441PD - Magnitude of clinical benefit of randomized controlled trials supporting US Food and Drug Administration approval of drugs for solid tumours

Sunday, 10 September: Special Session, Cost value and assessment tools of therapies in modern oncology 16:30 - 18:00, Alicante Auditorium

N Cherny (Jerusalem, Israel)

Principles and reflections on cost, value and sustainability of anticancer therapies
I Tannock (Toronto, Canada)

ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS): New version 1.1
N Cherny (Jerusalem, Israel)

Integrating the ESMO-MCBS in ESMO Clinical Practice Guidelines
G Pentheroudakis (Ioannina, Greece)

Implementation of the ESMO-MCBS scale
E de Vries (Groningen, Netherlands)

Discussion and conclusions, led by
E de Vries (Groningen, Netherlands)

Monday, 11 September: Proffered Paper Session; 16:30 - 18:00, Alicante Auditorium

1435O_PR - Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in Clinical Trials Supporting US Food and Drug Administration (FDA) Approval of Orphan vs. Non-orphan Drugs.

1436O_PR - How to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS

1437O_PR - Clinical Benefit of Randomized Controlled Trials (RCT) Supporting US Food and Drug Administration (FDA) Conversion from Accelerated to Full Approval

ESMO Asia 2016 Congress: December 2016

Friday, 16 December: Special Session; 14:30-16:00, Summit 2
During ESMO Asia 2016 Special Session, ESMO-MCBS and other scales to grade drugs was presented

View the webcast

ESMO 2016 Congress: October 2016

The scale was presented or referenced during the following sessions at the ESMO 2016 congress:

Saturday, 8 October: Poster Display; 13:00-14:00, Hall E
Abstract 1511P: TKIs in first-line for advanced NSCLC with activating EGFR-mutations: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized controlled trials

View the poster

Saturday, 8 October: Poster Discussion session; 16:30-17:30, room Helsinki
Abstract:1365PD Do contemporary randomized controlled trials meet ESMO thresholds for clinically meaningful benefit?

View the poster

Sunday, 9 October: Special Session; 14:45-16:15, room Helsinki
Clinical benefit of Cancer Drugs

View three webcasts

Monday, 10 October: Special Symposium; 11:00-12:30, room Helsinki
ESMO’s initiatives to reduce disparities in cancer care: Promoting access to valuable drugs focusing in the magnitude of clinical benefit

Monday, 10 October: Proffered Paper session; 16:30-18:00, room Oslo
Abstract 1364O: The ESMO-Magnitude of Clinical Benefit Scale (MCBS) in rare tumor entities: A real life experience at the Medical University Vienna

View the webcast

December 2015

During an ESMO Asia 2015 Special Session, Resource constraints as a barrier to lung cancer management: Developing nations, C. Zielinski presented the ESMO Magnitude of Clinical Benefit Scale.

Watch C. Zielinski's presentation

September 2015

Elisabeth de Vries

Elisabeth de Vries presenting the ESMO Magnitude of Clinical Benefit Scale during the ESMO Society session at ECC 2015

The scale was presented at the ESMO Society Session (28 September) during the European Cancer Congress 2015 in Vienna, Austria. E.G. de Vries, Netherlands, presented the scale and A. Eniu, Romania explained how the scale is applied using the data from the ESMO Anti-Neoplastic Medicines Surveys.

Watch E. G. de Vries's presentation

Watch A. Eniu’s presentation

In addition, aspects of the ESMO-MCBS were highlighted and discussed during three further sessions at ECC 2015:

  • ESO Society Session: ‘Is innovation Affordable?’, 26 September: The ESMO initiative on affordable drugs, Speaker: M. Piccart (Belgium)
  • Oncopolicy Forum: Inequalities in Treatment Outcomes, 27 September: The Value of anticancer treatment, Speaker: E. G. de Vries (Netherlands)
  • Special Session: Evaluating Clinical Benefit of Cancer Drugs Across Tumours, 28 September: Chair: E.G. de Vries (Netherlands); Clinical Benefit scale: The European proposal, Speaker: M. Piccart (Belgium); Clinical Benefit scale: The challenge of fairness, Speaker: U. Dafni (Greece)

Webcasts of the above presentations can be accessed via the ECC 2015 website. Select 'webcasts' from the top menu.

May 2015

ESMO-MCBS presented at the ESMO/ASCO Joint Session (30 May) during ASCO 2015, Chicago

Future Presentations

World Cancer Congress 2016, Paris, France (31 October – 3 November 2016). The ESMO Magnitude of clinical benefit scale and the value of cancer care, E. G. de Vries (Netherlands)